Nicardipine versus nitroprusside for breakthrough hypertension following carotid endarterectomy - 03/09/11
, David A Thompson, MS, RN a, b, †, Michael J Breslow, MD a, b, ‡, Pamela A Lipsett, MD a, b, ‡, Brian A Rosenfeld, MD a, b, §Abstract |
Study Objective: To evaluate the effectiveness of nicardipine and nitroprusside for breakthrough hypertension following carotid endarterectomy.
Design: Prospective, randomized, double-blind, controlled effectiveness trial.
Setting: University-based surgical intensive care unit.
Patients: 60 ASA physical status I, II, III, and IV patients experiencing breakthrough hypertension at the time of admission to the intensive care unit (ICU).
Interventions: Patients received either nicardipine (n = 29) and placebo or nitroprusside (n = 31) and placebo for up to 6 hours postoperatively. Loading doses of nicardipine were provided, but placebo was used as a load for patients randomized to nitroprusside.
Measurements and Main Results: Rapidity and variability of blood pressure (BP) control were assessed. During the first 10 minutes, 83% of nicardipine patients compared to 23% of nitroprusside-treated patients, achieved BP control (p < 0.01). Following initial control, 12 nicardipine- and 24 nitroprusside-treated patients required additional titration of their infusions to maintain blood pressure within the targeted range (p < 0.05). No patient suffered a stroke, myocardial infarction, or was returned to the operating room (OR) for bleeding.
Conclusions: Nicardipine administration produced more rapid BP control, most likely related to the administration of a loading dose. In addition to more rapid control, nicardipine-treated patients had less variability in BP and required significantly fewer additional interventions. Although no patient suffered a major event during this study, this study was not powered sufficiently to assess safety.
Le texte complet de cet article est disponible en PDF.Keywords : Blood pressure, hypertension, nicardipine, nitroprusside, vascular surgery
Plan
| This study was supported in part by a grant from Wyeth-Ayerst Pharmaceuticals. |
Vol 13 - N° 1
P. 16-19 - février 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
